Abstract In the present study, we investigated the effects of a Kampo medicine hangeshashinto (TJ-14) on the production of prostaglandin E 2 (PGE 2 ), interleukin (IL)-6 and IL-8 by human gingival fibroblasts (HGFs) treated with lipopolysaccharide (LPS) from Porphyromonas gingivalis. HGFs proliferation was dose-dependently decreased with hangeshashinto at days 3 and 7. However, treatment with LPS (10 ng/ml), hangeshashinto (up to 1 mg/ml) and their combinations for 24 h did not affect the viability of HGFs. Hangeshashinto dose-dependently suppressed LPS-induced PGE 2 production but did not alter basal PGE 2 level. Hangeshashinto weakly decreased LPS-induced IL-6 and IL-8 productions. Hangeshashinto decreased cyclooxygenase (COX)-1 and COX-2 activities to approximately 60% at 1 mg/ml. Hangeshashinto decreased cytoplasmic phospholipase A 2 (cPLA 2 ) expression and LPS-induced COX-2 expression but not affected annexin1 expression. Hangeshashinto weakly suppressed LPS-induced extracellular signal-regulated kinase (ERK) phosphorylation, which is known to lead to ERK activation and cPLA 2 phosphorylation. These results suggest that hangeshashinto decreased PGE 2 production by (1) suppression of cPLA 2 and LPS-induced COX-2 expression, and to a lesser extent, (2) inhibition of COX-2 activity and (3) inhibition of cPLA 2 phosphorylation and its activation via inhibition of ERK phosphorylation. Moreover, it is also suggested that hangeshashinto may be useful to improve gingival inflammation in periodontal disease.
Introduction
Caries and periodontal disease are two major oral diseases and are considered to be biofilm infectious diseases 1) . In particular, periodontal disease is highly prevalent and can affect most of the Recently, we reported that a kampo medicine shosaikoto and orento (TJ-120) suppressed lipopolysaccharide (LPS)-induced PGE 2 production by HGFs, and suggested that these kampo medicines have anti-inflammatory effects in periodontal disease 3, 4) . Other kampo medicine, hangeshashinto (TJ- 14) , has been used for inflammatory diseases such as acute or chronic gastrointestinal catarrh, nervous gastritis and stomatitis 5) similar to orento 6) .
Hangeshashinto is reported to have the capabilities for the protection of the gastric mucosa 7) , the antidiarrheal effect 8, 9) , the anti-inflammatory effect [9] [10] [11] and the enhancement of large intestinal water absorption 12) . From these indications, we considered that hangeshashinto could be useful for periodontal disease. 18) in the presence of LPS, these mediators and cytokines in periodontal tissues are thought to be
Materials and Methods

Reagents
Powder of hangeshashinto was obtained from Tsumura & Co.
(Tokyo, Japan), and its component was indicated in Table 1 .
Hangeshashinto was suspended in Dulbecco's modified Eagle's medium (D-MEM, Sigma, St. Louis, MO) containing 10% heatinactivated fetal calf serum, 100 units/ml penicillin and 100 mg/ ml streptomycin (culture medium) and was rotated at 4 overnight. Then, the suspension was centrifuged and the supernatant was filtrated through 0.45 µm-pore membrane. LPS from Porphyromonas gingivalis 381 was provided by Drs. Tatsuji Nishihara and Nobuhiro Hanada (National Institutes of Public Health, Wako, Japan). Phorbol 12-myristate 13-acetate (PMA, Sigma) was dissolved in dimethyl sulfoxide (DMSO, Nacalai tesque, Kyoto, Japan).
Cells
HGFs were prepared from free gingiva during the extraction of an impacted tooth with the informed consents of the subjects who consulted Matsumoto Dental University Hospital. The free gingival tissues were cut into pieces and seeded on a 24-well plates (AGC Techno Glass Co., Chiba, Japan). HGFs were maintained in Dulbecco's modified Eagle's medium (D-MEM; Sigma, St.
Louis, MO) containing 10% heat-inactivated fetal calf serum (FCS), 100 units/ml penicillin and 100µg/ml streptomycin, at 37 in a humidified atmosphere of 5% CO 2 . HGFs were used between 10th to 20th passages in the assays. This study was approved by the Ethical Committee of Matsumoto Dental University.
Cell viability
The numbers of cells were measured using WST- 
Measurement of cyclooxygenase activity
The effects of hangeshashinto on the activities of cyclooxygenase 66.9 ± 3.5** 59.0 ± 6.0** Data represent the mean ± S.D. (n=3). **P < 0.01, significant differences from control (0 mg/ml) by Dunnett's method. Table 2 Effect of hangeshashinto on COX activities 
A B C
The antibodies against COX-2 (sc-1745, 1:500 dilution), 
Statistical analysis
Differences between control group and experimental groups were evaluated by Dunnett method (Table 2) 
A B C
The effect of hangeshashinto on HGFs proliferation
First, we examined the effect of hangeshashinto on HGFs proliferation. In the absence of presence of LPS, hangeshashinto significantly suppressed HGFs proliferation in the dose-dependent manner ( Fig. 1A and 1B) . In particular, HGFs treated with 1 mg/ ml of hangeshashinto were almost dead at day 7. Moreover, HGFs proliferation was slightly but significantly suppressed by LPS treatment (Fig. 1B) .
The effect of hangeshashinto on PGE 2 , IL-6 and IL-8 production
We examined whether hangeshashinto affects the productions of PGE 2 and inflammatory cytokines (IL-6 and IL-8) by HGFs.
Because hangeshashinto affects cell viability, the concentrations of PGE 2 , IL-6 and IL-8 were needed for adjustment by the viable cell numbers. When HGFs were treated with LPS and hangeshashinto for 24 h, the viability of HGFs were hardly affected (Fig. 1C) .
HGFs without any treatment produced low level of PGE 2 .
Hangeshashinto significantly suppressed LPS-induced PGE 2 production in a dose-dependent manner ( Fig. 2A) . IC 50 of hangeshashinto for LPS-induced PGE 2 production was 0.019 mg/ ml and its 95% confidential interval was 0.010-0.028 mg/ml.
However, hangeshashinto had little effect on PGE 2 production in the absence of LPS.
In the absence of LPS, IL-6 and IL-8 productions were not altered at 0.01 and 0.1 mg/ml of hangeshashinto but increased at 1 mg/ml of hangeshashinto ( Fig. 2B and C) . In contrast, hangeshashinto weakly decreased LPS-induced IL-6 and IL-8 productions ( Fig. 2B and C) .
The effect of hangeshashinto on COX activities
Because PGE 2 production was regulated by COXs and suppressed by acid NSAIDs such as aspirin and diclofenac sodium, which inhibit COXs activities, we examined whether hangeshashinto inhibits COX-1 and COX-2 activities. Hangeshashinto decreased both COX-1 and COX-2 activities to approximately 60% ( Table   2 ).
The effect of hangeshashinto on molecular expressions in arachidonic acid cascade
We examined whether hangeshashinto affects the molecular expression in arachidonic acid cascade. cPLA 2 is the most upstream enzyme in arachidonic acid cascade and releases arachidonic acid from plasma membrane. Hangeshashinto decreased cPLA 2 expression in the absence or presence of LPS (Fig. 3) . COX-2 was not detected in the absence of LPS, and induced by LPS treatment. LPS-induced COX-2 expression was increased with up to 0.1 mg/ml of hangeshashinto and slightly decreased with 1 mg/ml of hangeshashinto (Fig. 3) . Annexin1, also named as lipocortin1, is the anti-inflammatory mediator produced by glucocorticoids and inhibits the cPLA 2 activity 19, 20) .
However, both LPS and hangeshashinto showed no effect on annexin1 expression (Fig. 3) .
The effects of hangeshashinto on ERK phosphorylation
cPLA 2 is reported to be directly phosphorylated at Ser505 by ERK, resulting in cPLA 2 activation 21, 22) . Therefore, we examined whether hangeshashinto suppresses LPS-induced ERK phophorylation.
ERK phosphorylation was enhanced 0.5 h after LPS treatment and thereafter was attenuated, and 1 mg/ml of hangeshashinto weakly suppressed LPS-induced ERK phosphorylation at 0.5 h to 2 h (Fig. 4) .
Discussion
In the present study, we examined the effect of hangeshashinto in LPS-treated HGFs. Hangeshashinto suppressed LPS-induced PGE 2 production, but to a lesser extent IL-6 and IL-8, by HGFs as well as shosaikoto and orento 3, 4) . It is widely known that PGE 2 leads to inflammatory responses such as vasodilation, enhanced vascular permeability and pain generation. Acid NSAIDs shows anti-inflammatory effect by suppression of PGE production even though they did not affect IL-6 and IL-8 productions. The findings that hangeshashinto suppresses LPS-induced PGE2 production to a basal level suggest that hangeshashinto also has antiinflammatory effects in periodontal disease and that its effects are mainly mediated by suppression of PGE 2 production.
In the present study, the findings that hangeshashinto suppressed cPLA 2 expression, LPS-induced COX-2 expression and COX-2 activity were obtained. However, hangeshashinto suppressed COX-2 activity to approximately 60% at 1 mg/ml.
Moreover, hangeshashinto weakly suppressed LPS-induced ERK phosphorylation. Because phosphorylated ERK activates cPLA 2 through its phosphorylation 21, 22) , it is suggested that hangeshashinto suppresses LPS-induced cPLA 2 activation. However, the extent may be low. Therefore, the anti-inflammatory effect of hangeshashinto is assumed to be mainly the suppression of cPLA 2 expression and COX-2 expression, and to a lesser extent, the suppression of COX-2 activity and cPLA 2 activation.
In general, steroidal anti-inflammatory drugs (SAIDs) suppress However, the components remain to be elucidated. Moreover, ogon may suppresses cPLA 2 expression. However, its possibility is low because shosaikoto which also contains ogon did not affect cPLA 2 expression 3) .
We demonstrated that orento suppresses LPS-induced ERK phosphorylation and further cPLA 2 phosphorylation, and suggested that oren, kankyo and/or keihi may have its action 4) .
Hangeshashinto also suppressed LPS-induced ERK phosphorylation, but its extent was weak. Considering the difference of oren content in hangeshashinto and orento, it is s u g g e s t e d t h a t o r e n s u p p r e s s e s L P S -i n d u c e d E R K phosphorylation. In fact, berberine, which is the main component of oren, is reported to suppress ERK phosphorylation in vascular smooth muscle cell 26) and mouse macrophages 27) . Because hangeshashinto suppressed LPS-induced ERK phosphorylation weakly, the inhibitory action of hangeshashinto on cPLA 2 activation is assumed to be weak compared to orento.
Many studies demonstrated that NSAIDs administration prevents gingival inflammation (reviewed in ref.
2). And several clinical studies indicated that the concentration of PGE 2 in gingival crevicular fluid (GCF) is increased in periodontal disease 28) and is decreased by oral administration or mouse wash of NSAIDs 29, 30) .
Considering the facts that both NSAIDs and hangeshashinto suppress PGE 2 production, it is possible that administration of hangeshashinto also decreases PGE 2 concentration in GCF and results in the improvement of gingival inflammation. Therefore, hangeshashinto may be useful for the improvement of gingival inflammation in periodontal disease. Importantly, hangeshashinto did not affect basal level of PGE 2 . Because PGE 2 produced by COX-1 protects gastric mucosa, these results suggest that hangeshashinto may have minimal gastrointestinal dysfunction.
In summary, we demonstrated that hangeshashinto suppresses cPLA 2 and COX-2 expressions and to a lesser extent COX-2 activity, and results in PGE 2 production by HGFs. Hangeshashinto may be useful for the improvement of inflammation in periodontal disease.
and (2) the oren content in hangeshashinto (5.4%) is less than one-half of that in orento (12.5%). Hangeshashinto suppressed COX-2 expression, COX-2 activity and cPLA 2 expression, while orento increased COX-2 and cPLA 2 expressions and did not affect COX-2 activity 4) . These results suggest that ogon suppresses COX-2 expression and activity.
Indeed, ogon contains several flavonoids such as baicalin, baicalein and wogonin 23) , and these flavonoids suppress COX-2 expression in several cells [23] [24] [25] . Therefore, hangeshashinto suppresses COX-2 expression as well as shosaikoto 3) .
Previously, hangeshashinto is reported to inhibit COX-2 activity although which the herbs in hangeshashinto inhibit COX-2 activity remain unclear 11) . The comparison of these two kampo
